Table 3-.
Patient Characteristics and outcomes of specific regimens* at next line after T0
| All regimens | Any Daratumumab | Daratumumab + IMiD | Daratumumab + PI | Elotuzumab + IMiD | Any Carfilzomib | Carfilzomib + IMiD | Carfilzomib + Alkylator | Any Alkylator | “PACE”-like | Bendamustine | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N=249 | N=57 | N=41 | N=13 | N=19 | N=68 | N=34 | N=19 | N=90 | N=24 | N=15 | |
| Characteristics | |||||||||||
| High risk FISH | 71 (28.5%) | 16 (28.1%) | 11 (26.8%) | 5 (38.5%) | 3 (15.8%) | 16 (23.2%) | 7 (20.0%) | 6 (31.6%) | 34 (37.8%) | 8 (33.3%) | 6 (40.0%) |
| Prior lines# | 5 (2–17) | 5 (2–17) | 5 (2–9) | 5 (2–17) | 4 (2–10) | 4 (2–9) | 4 (2–7) | 4 (2–9) | 5 (2–12) | 4.5 (3–9) | 6 (4–12) |
| ≥Triple-refractory | 197 (79.1%) | 49 (86.0%) | 33 (80.5%) | 12 (92.3%) | 18 (94.7%) | 43 (62.3%) | 19 (54.3%) | 14 (73.7%) | 77 (85.6%) | 21 (87.5%) | 15 (100%) |
| Penta-refractory | 63 (25.6%) | 9 (15.8%) | 3 (7.3%) | 5 (38.5%) | 6 (31.6%) | 8 (11.6%) | 2 (5.9%) | 2 (10.5%) | 29 (32.2%) | 5 (20.8%) | 6 (40.0%) |
| Carfilzomib-refractory | 116 (46.6%) | 25 (43.9%) | 17 (41.5%) | 4 (30.8%) | 13 (68.4%) | 10 (14.7%) | 2 (5.9%) | 2 (10.5%) | 49 (54.4%) | 14 (58.3%) | 9 (60.0%) |
| Pomalidomide-refractory | 162 (65.1%) | 33 (57.9%) | 23 (56.1%) | 9 (69.2%) | 13 (68.4%) | 38 (55.9%) | 18 (52.9%) | 12 (63.2%) | 69 (76.7%) | 18 (75.0%) | 13 (86.7%) |
| Carfilzomib and Pomalidomide-refractory | 89 (35.7%) | 17 (29.8%) | 10 (24.4%) | 4 (30.8%) | 10 (52.6%) | 8 (11.8%) | 1 (2.9%) | 2 (10.5%) | 43 (47.8%) | 11 (45.8%) | 8 (53.3%) |
| Response to next line of therapy after T0 | |||||||||||
| PD | 66 (26.5%) | 19 (33.3%) | 10 (24.4%) | 7 (53.8%) | 5 (26.3%) | 16 (23.5%) | 6 (17.6%) | 5 (26.3%) | 18 (20.0%) | 5 (20.8%) | 6 (40.0%) |
| SD | 84 (33.7%) | 22 (38.6%) | 17 (41.5%) | 4 (30.8%) | 6 (31.6%) | 23 (33.8%) | 13 (38.2%) | 4 (21.1%) | 26 (28.9%) | 6 (25.0%) | 4 (26.7%) |
| PR | 51 (20.5%) | 9 (15.8%) | 8 (19.5%) | 0 (0.0%) | 4 (21.0%) | 11 (16.2%) | 5 (14.7%) | 4 (21.1%) | 25 (27.8%) | 8 (33.3%) | 3 (20%) |
| VGPR | 22 (8.8%) | 5 (8.8%) | 5 (12.2%) | 0 (0.0%) | 0 (0.0%) | 10 (14.7%) | 5 (14.7%) | 4 (21.1%) | 11 (12.2%) | 2 (8.3%) | 1 (6.7%) |
| CR/sCR | 5 (2.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.5%) | 1 (2.9%) | 1 (5.3%) | 4 (4.4%) | 1 (4.2%) | 1 (6.7%) |
| ORR | 78 (31.3%) | 14 (24.6%) | 15 (36.6%) | 0 (0.0%) | 4 (21.1%) | 22 (32.3%) | 11 (32.4%) | 9 (47.4%) | 40 (44.4%) | 11 (45.8%) | 5 (33.3%) |
| N.A | 15 (6.0%) | 2 (3.5%) | 1 (2.4%) | 2 (15.4%) | 4 (21.0%) | 7 (10.3%) | 4 (11.8%) | 1 (5.9%) | 6 (6.7%) | 1 (5.6%) | 0 (0.0%) |
| PFS and OS [in months (95% C.I.)] on next line after T0 | |||||||||||
| PFS | 3.4 (2.8–4.0) | 3.9 (2.7–5.1) | 4.5 (2.8–6.3) | 1.8 (1.2–2.5) | 2.6 (1.1–4.1) | 4.2 (2.3–6.2) | 4.1 (3.1–5.1) | 5.7 (1.6–9.7) | 3.2 (2.9–3.5) | 3.0 (2.5–3.4) | 3.2 (2.3–4.1) |
| OS | 9.31 (8.1–10.6) | 11.4 (8.8–14.0) | 12.6 (8.5–16.6) | 7.7 (0.0–19.6) | 8.3 (1.9–14.6) | 10.9 (9.5–12.4) | 11.2 (8.9–13.6) | 12.7 (5.9–19.5) | 7.7 (4.9–10.5) | 5.9 (2.6–9.1) | 9.3 (5.0–13.6) |
*
Regimen categories are not mutually exclusive, # median (range); N.A. = not available; PACE = cisplatin, adriamycin, cyclophosphamide and etoposide.